CD80 (B7-1) Monoclonal Antibody (2D10.4), Brilliant Ultra Violet™ 737, eBioscience™, Invitrogen™

Description

• The 2D10.4 monoclonal antibody reacts with human CD80 (B7-1), a 60 kDa member of the Ig superfamily
• CD80 is expressed by activated B cells, macrophages and dendritic cells
• In addition, activated T cells express this antigen
• CD80 has high affinity for binding to two T cell surface antigens, CD28 and CD152 (CTLA-4)
• The interaction of CD28 and CD152 with CD80 is crucial in T-B cell communication leading to activation of T and B cells, respectively
• Applications Reported: This 2D10.4 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This 2D10.4 antibody has been pre-diluted and tested by flow cytometric analysis of Daudi cells
• This may be used at 5 μL (0.5 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• Brilliant Ultraviolet 737 is a tandem dye that emits at 732 nm and is intended for use on cytometers equipped with an ultraviolet (355 nm) laser
• CD80 (B7-1) and CD86 (B7-2) are ligands of T cell critical costimulatory molecule CD28, and of an inhibitory receptor CTLA-4 (CD152)
• Both B7 molecules are expressed on professional antigen-presenting cells and are essential for T cell activation, and both molecules can also substitute for each other in this process
• CD80 is rapidly induced on the surface of in vitro activated B cells, with Epstein Barr Virus (EBV) transformed B cell lines, with Burkitts lymphoma cell lines, with freshly isolated follicular B lymphoma cells, T cells, and monocytes
• The B-lymphocyte activation antigen B7-1 provides regulatory signals for T lymphocytes as a consequence of binding to the CD28 and CTLA4 ligands of T cells
• Diseases associated with CD80 dysfunction include gallbladder squamous cell carcinoma and myocarditis.